Citations

Clear

4847 citation(s) found for "Yu, Eric".

Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer’s disease
Vermunt, Lisa , Dicks, Ellen , Wang, Guoqiao , Dincer, Aylin , Flores, Shaney , Keefe, Sarah , Berman, Sarah , Cash, David M. , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Fox, Nick C. , Graff‐Radford, Neill R. , Hassenstab, Jason , Laske, Christoph , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Morris, John C. , Noble, James M. , Perrin, Richard J. , Visser, Pieter Jelle , Bateman, Randall J. , Gordon, Brian A. , (DIAN), Dominantly Inherited Alzheimer Network, Amtashar, Fatima, Bodge, Courtney, Brandon, Susan E. , Buck, Jill , Buckles, Virginia, Chea, Sochenda, Chrem, Patricio, Chui, Helena C., Cinco, Jake, Jack, Clifford, D’Mello, Mirelle , Donahue, Tamara, Douglas, Jane, Edigo, Noelia, Erekin-Taner, Nilufer, Fagan, Anne M. , Farlow, Marty, Farrar, Angela, Feldman, Howard , Flynn, Gigi, Franklin, Erin , Gant, Cortaiga, Gardener, Samantha L. , Gray, Julia, Gurney, Jenny , Hassenstab, Jason, Hirohara, Mie, Hornbeck, Russ C. , DiBari, Siri Houeland, Ikonomović, Snežana, Jerome, Gina, Klunk, William E. , Kuder-Buletta, Elke, Marcus, Daniel S. , Mason, Neal Scott, Maue-Dreyfus, Denise, Montoya, Lucy, Nagamatsu, Akem, Neimeyer, Katie, Norton, Joanne, Raichle, Marc, Ringman, John M. , Roh, Jee Hoon , Shiroto, Tomoyo, Sigurdson, Wendy, Sparks, Paige, Swisher, Laura, Taddei, Kevin , Wang, Peter, Weiner, Mike, Wolfsberger, Mary, Xiong, Chengjie, Tijms, Betty M , Gordon, Brian A , Cruchaga, Carlos , Bateman, Randall J , Masters, Colin L , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Roh, Jee Hoon , Cash, David M , Feldman, Howard H , Berman, Sarah , Ghetti, Bernardino , Karch, Celeste M. , McDade, Eric , Schofield, Peter R. , Xiong, Chengjie , Scheltens, Philip , Benzinger, Tammie L.S. , Tijms, Betty M. , (DIAN), Dominantly Inherited Alzheimer Network, Allegri, Ricardo , Brandon, Susan, Brooks, William S. , Buck, Jill, Chui, Helena C. , Fujii, Hisako , Goate, Alison , Goldman, Jill , Hassenstab, Jason, Holtzman, David M. , Ikeuchi, Takeshi , Jucker, Mathias , Kasuga, Kensaku , Kawarabayashi, Takeshi , Koeppe, Robert A. , Martins, Ralph N. , Shimada, Hiroyuki , Shoji, Mikio , Sohrabi, Hamid R. , Suzuki, Kazushi , Wang, Jen Chin C. , Xiong, Chengjie, Xu, Xiong, Noble, James M

Mayo Clinic

Brain Communications | July 15, 2020 | Volume: 2 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcaa102 | PMID 32954344 Get It

Abstract Structural grey matter covariance networks provide an individual quantification of morphological patterns in the brain. The network integrity is disrupted in sporadic Alzheimer’s disease, and network properties show associations with the level of amyloid pathology and cognitive decline. Therefore, these network properties might be disease progression markers. However, it remains unclear when and how grey matter network integrity changes with disease progression. We investigated these questions in autosomal dominant Alzheimer’s disease mutation carriers, whose conserved age at dementia onset allows individual staging based upon their estimated years to symptom onset. From the Dominantly Inherited Alzheimer Network observational cohort, we selected T1-weighted MRI scans from 269 mutation carriers and 170 non-carriers (mean age 38 ± 15 years, mean estimated years to symptom onset −9 ± 11), of whom 237 had longitudinal scans with a mean follow-up of 3.0 years. Single-subject grey matter networks were extracted, and we calculated for each individual the network properties which describe the network topology, including the size, clustering, path length and small worldness. We determined at which time point mutation carriers and non-carriers diverged for global and regional grey matter network metrics, both cross-sectionally and for rate of change over time. Based on cross-sectional data, the earliest difference was observed in normalized path length, which was decreased for mutation carriers in the precuneus area at 13 years and on a global level 12 years before estimated symptom onset. Based on longitudinal data, we found the earliest difference between groups on a global level 6 years before symptom onset, with a greater rate of decline of network size for mutation carriers. We further compared grey matter network small worldness with established biomarkers for Alzheimer disease (i.e. amyloid accumulation, cortical thickness, brain metabolism and cognitive function). We found that greater amyloid accumulation at baseline was associated with faster decline of small worldness over time, and decline in grey matter network measures over time was accompanied by decline in brain metabolism, cortical thinning and cognitive decline. In summary, network measures decline in autosomal dominant Alzheimer’s disease, which is alike sporadic Alzheimer’s disease, and the properties show decline over time prior to estimated symptom onset. These data suggest that single-subject networks properties obtained from structural MRI scans form an additional non-invasive tool for understanding the substrate of cognitive decline and measuring progression from preclinical to severe clinical stages of Alzheimer’s disease.
Human Papillomavirus–Associated Anogenital Pathology in Females With HPV‐Positive Oropharyngeal Squamous Cell Carcinoma
Larish, Alyssa , Moore, Eric J. , Routman, David M. , Janus, Jeffrey R. , Price, Katharine A. , Neben-Wittich, M.A. , Foote, Robert L. , Abel, Kathryn M. Van , Yin, Linda, Glaser, Gretchen , Moore, Eric, Bakkum-Gamez, Jamie, Routman, David, Ma, Daniel, Price, Daniel, Janus, Jeffrey, Price, Katharine, Chintakuntlawar, Ashish, Neben-Wittich, Michelle, Foote, Robert, Van Abel, Kathryn, Van Abel, Kathryn M , Routman, David M , Yin, Linda X. , Bakkum‐Gamez, Jamie N. , Daniel, J. , Price, Daniel L. , Chintakuntlawar, Ashish V.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 14, 2020 | Volume: 164 | Issue: 2 | Pages: 369-374

10.1177/0194599820941499 | PMID 32663054 Get It

We sought to determine the incidence and location of human papillomavirus (HPV)–associated anogenital disease in women with HPV‐positive oropharyngeal squamous cell carcinoma (OPSCC) via a retrospective cohort study with prospective contact to update history at Mayo Clinic in Rochester, Minnesota. Females undergoing treatment for nonmetastatic HPV‐positive OPSCC from 2011 to 2019 were identified. Clinical history and outcomes were abstracted from medical records. Patients without documented anogenital history were contacted, consented, and administered a survey, and external records were requested and reviewed. Seventeen of 46 patients (37.0%) had a history of anogenital HPV‐associated disease, and 16 of 17 (94.1%) required procedures to diagnose or treat HPV lesions. The cervix was the most common site (16/17, 94.1%). Procedures included colposcopy (n = 6), cervical excision (n = 3), cryotherapy (n = 4), and hysterectomy (n = 3). One case of fatal cervical carcinoma was noted, diagnosed 1 year following OPSCC. Three of 17 (17.6%) had HPV‐related vulvovaginal disease, and 1 of 17 had anal disease. Patients with a history of HPV‐positive OPSCC may be at elevated risk for HPV‐associated anogenital disease.
Dermal Fat Grafting to Reconstruct the Parotidectomy Defect Normalizes Facial Attention
Anderies, Barrett J. , Dey, Jacob K. , Gruszczynski, Nelson , Moore, Eric J. , Janus, Jeffrey R. , Gruszczynski, Nelson R , Moore, Eric J , Dey, Jacob K , Price, Daniel L.

Mayo Clinic

The Laryngoscope | July 13, 2020 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/lary.28890 | PMID 32658339 Get It

Objectives/HypothesisUse validated eye‐tracking technology to objectively measure 1) the attentional distraction of facial contour defects after superficial and total parotidectomy and 2) changes in attentional distraction with abdominal dermal fat graft reconstruction.MethodsStandardized frontal and oblique facial images of 16 patients who had undergone superficial or total parotidectomy with or without fat graft reconstruction; four normal controls were obtained. One hundred casual observers were recruited to view these images, and gaze data were collected using a Tobii Pro eye‐tracking system. Gaze durations for predefined facial areas of interest were analyzed using mixed‐effects linear regression to test study hypotheses.ResultsFor frontal images, total parotidectomy increased gaze to the operated parotid area compared to the contralateral nonoperated parotid area (92 milliseconds, 95% confidence interval [CI]: 48‐138 milliseconds, P < .001). Fat grafting normalized the attentional distraction, with no difference in gaze time on the operated parotid region compared to normal control faces (P = .414). For oblique images, total parotidectomy increased gaze to the operated parotid area compared to the contralateral nonoperated parotid area (658 milliseconds, 95% CI: 463‐854 milliseconds, P < .001). Fat grafting normalized this attentional distraction, with no difference in gaze time on the operated parotid region compared to normal control faces (P = .504). In both views, superficial parotidectomy demonstrated no significant attentional distractions, with or without fat grafting.ConclusionsThis eye‐tracking study objectively demonstrates that total parotidectomy results in a facial contour deformity that is distracting to observers, whereas superficial parotidectomy does not. For total parotidectomy, this attentional distraction can be normalized with dermal fat graft reconstruction.Level of Evidence3b Laryngoscope, 131:E124–E131, 2021
Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention
Abraham, Neena S. , Inselman, Jonathan , Sangaralingham, Lindsey R. , Shah, Nilay D. , Yao, Xiaoxi , Yang, Eric H. , Noseworthy, Peter A. , Herrin, Jeph , Ngufor, Che

Mayo Clinic

Alimentary Pharmacology & Therapeutics | July 13, 2020 | Volume: 52 | Issue: 4 | Pages: 646-654

10.1111/apt.15790 | PMID 32657466 Get It

SummaryBackgroundGastrointestinal bleeding (GIB) frequently occurs following percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) with the prescription of P2Y12 inhibiting antiplatelet agents. Compared with clopidogrel, the newer P2Y12 inhibitors lower major adverse cardiac events with similar or possibly higher major bleeding events. The comparative GIB rates of these medications remain poorly understood.AimTo compare GIB rates associated with clopidogrel, prasugrel and ticagrelor using national medical and pharmacy claims data from privately insured and Medicare Advantage enrollees .MethodsPropensity score and inverse probability treatment weighting were used to balance baseline characteristics among treatment groups. The 1‐year GIB risk was calculated using weighted Cox proportional hazard models and expressed as hazard ratios (HR) with 95% confidence intervals (CI) and number needed to harm (NNH).ResultsWe identified 37 019 patients with ACS (non‐ST elevation ACS [NSTE‐ACS] and ST‐elevation myocardial infarction [STEMI]) within 14 days of a PCI (mean age 63 years and 70% male). Clopidogrel prescription was most common (69%) with prasugrel (16%) and ticagrelor (14%) prescribed less frequently. When compared with clopidogrel, ticagrelor was associated with a 34% risk reduction (HR 0.66; 95% CI: 0.54–0.81) in GIB overall and with NSTE‐ACS, and a 37% GIB risk reduction (HR 0.63; 95% CI: 0.42–0.93) in STEMI patients. When compared with clopidogrel, prasugrel was associated with a 21% risk reduction (HR 0.79; 95% CI: 0.64–0.97) overall, a 36% GIB risk reduction (HR 0.64; 95% CI: 0.49–0.85) in STEMI patients but no reduction of GIB risk in NSTE‐ACS patients.ConclusionsIn the first year following PCI, ticagrelor or prasugrel are associated with fewer GIB events than clopidogrel.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Shah, Nina , Aiello, Jack, Avigan, David , Borrello, Ivan , Chari, Ajai , Cohen, Adam D. , Ganapathi, Karthik A. , Gray, Lissa , Green, Damian, Krishnan, Amrita , Lin, Yi , Manasanch, Elisabet E. , Munshi, Nikhil C. , Rapoport, Aaron P. , Smith, Eric L. , Vij, Ravi , Dhodapkar, Madhav V. , Cohen, Adam D , Chari, Ajai , Lin, Yi , Berdeja, Jesús G. , Green, Damian J , Nooka, Ajay K.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 13, 2020 | Volume: 8 | Issue: 2 | Pages: e000734

10.1136/jitc-2020-000734 | PMID 32661116 Get It

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor (CAR) T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.
Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk
Petersen, Paneen S., Schmit, Stephanie L. , Drew, David A. , Berndt, Sonja I. , Brenner, Hermann , Casey, Graham , Chang‐Claude, Jenny , Gallinger, Steven , Gruber, Stephen B. , Haile, Robert W. , Harrison, Tabitha A. , Hoffmeister, Michael , Jacobs, Eric J. , Joshi, Amit D. , Li, Li , Lindor, Noralane M. , Martín, Vicente , Maclnnis, Robert J., Moreno, Vı́ctor , Nan, Hongmei , Rennert, Gad , Slattery, Martha L. , Thibodeau, S. N., Weinstein, Stephanie J. , Woods, Michael O. , Peters, Ulrike , Brenner, Hermann , Rennert, Gad , Drew, David A , Brenner, Hermann , Gruber, Stephen B , Haile, Robert W , Harrison, Tabitha A , Hoffmeister, Michael , Martín, Vicente , Milne, Roger L , Maclnnis, Robert , Moreno, Victor , Potter, John D , Rennert, Gad , Slattery, Martha L , Thibodeau, Steve N, Weinstein, Stephanie J , Rennert, Gad , Brenner, Hermann , Nan, Hongmei , Wang, Xiaoliang , Su, Yu-Ru , Bien, Stephanie A. , Albanes, Demetrius , Campbell, Peter T. , Jenkins, Mark A. , Lin, Yi , Marchand, Loı̈c Le , Milne, Roger L. , Newcomb, Polly A. , Potter, John D. , Chan, Andrew T. , White, Emily , Hsu, Li

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 10, 2020 | Volume: 29 | Issue: 9 | Pages: 1800-1808

10.1158/1055-9965.epi-19-1018 | PMID 32651213 Get It

Abstract Background: Regular use of nonsteroidal anti-inflammatory drugs (NSAID) is associated with lower risk of colorectal cancer. Genome-wide interaction analysis on single variants (G × E) has identified several SNPs that may interact with NSAIDs to confer colorectal cancer risk, but variations in gene expression levels may also modify the effect of NSAID use. Therefore, we tested interactions between NSAID use and predicted gene expression levels in relation to colorectal cancer risk. Methods: Genetically predicted gene expressions were tested for interaction with NSAID use on colorectal cancer risk among 19,258 colorectal cancer cases and 18,597 controls from 21 observational studies. A Mixed Score Test for Interactions (MiSTi) approach was used to jointly assess G × E effects which are modeled via fixed interaction effects of the weighted burden within each gene set (burden) and residual G × E effects (variance). A false discovery rate (FDR) at 0.2 was applied to correct for multiple testing. Results: Among the 4,840 genes tested, genetically predicted expression levels of four genes modified the effect of any NSAID use on colorectal cancer risk, including DPP10 (PG×E = 1.96 × 10−4), KRT16 (PG×E = 2.3 × 10−4), CD14 (PG×E = 9.38 × 10−4), and CYP27A1 (PG×E = 1.44 × 10−3). There was a significant interaction between expression level of RP11-89N17 and regular use of aspirin only on colorectal cancer risk (PG×E = 3.23 × 10−5). No interactions were observed between predicted gene expression and nonaspirin NSAID use at FDR &lt; 0.2. Conclusions: By incorporating functional information, we discovered several novel genes that interacted with NSAID use. Impact: These findings provide preliminary support that could help understand the chemopreventive mechanisms of NSAIDs on colorectal cancer.
Fetal Origins of Asthma: A Longitudinal Study from Birth to Age 36 Years
Guerra, Stefano , Stern, Debra A. , Sherrill, Duane L., Gilbertson-Dahdal, Dorothy , Wheatley, Courtney M. , Snyder, Eric M., Wright, Anne L., Martínez, Fernando D. , Lombardi, Enrico , Morgan, Wayne J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 10, 2020 | Volume: 202 | Issue: 12 | Pages: 1646-1655

10.1164/rccm.202001-0194oc | PMID 32649838 Get It

Abstract Rationale Deficits in infant lung function—including the ratio of the time to reach peak tidal expiratory flow to the total expiratory time (tptef/te) and maximal expiratory flow at FRC (V̇maxFRC)—have been linked to increased risk for childhood asthma. Objectives To examine the individual and combined effects of tptef/te and V̇maxFRC in infancy on risk for asthma and abnormalities of airway structure into mid-adult life. Methods One hundred eighty participants in the Tucson Children’s Respiratory Study birth cohort had lung function measured by the chest-compression technique in infancy (mean age ± SD: 2.0 ± 1.2 mo). Active asthma was assessed in up to 12 questionnaires between ages 6 and 36 years. Spirometry and chest high-resolution computed tomographic (HRCT) imaging were completed in a subset of participants at age 26. The relations of infant tptef/te and V̇maxFRC to active asthma and airway structural abnormalities into adult life were tested in multivariable mixed models. Measurements and Main Results After adjustment for covariates, a 1-SD decrease in infant tptef/te and V̇maxFRC was associated with a 70% (P = 0.001) and 55% (P = 0.005) increased risk of active asthma, respectively. These effects were partly independent, and two out of three infants who were in the lowest tertile for both tptef/te and V̇maxFRC developed active asthma by mid-adult life. Infant V̇maxFRC predicted reduced airflow and infant tptef/te reduced HRCT airway caliber at age 26. Conclusions These findings underscore the long-lasting effects of the fetal origins of asthma, support independent contributions by infant tptef/te and V̇maxFRC to development of asthma, and link deficits at birth in tptef/te with HRCT-assessed structural airway abnormalities in adult life.
Fully bayesian longitudinal unsupervised learning for the assessment and visualization of AD heterogeneity and progression
Poulakis, Konstantinos , Ferreira, Daniel , Pereira, Joana B. , Vemuri, Prashanthi , Westman, Eric , Vemuri, Prashanthi , Westman, Eric , Ferreira, Daniel , Smedby, Örjan

Mayo Clinic

Aging | July 9, 2020 | Volume: 12 | Issue: 13 | Pages: 12622-12647

10.18632/aging.103623 | PMID 32644944 Get It

Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk
Yuan, Fangcheng , Hung, Rayjean J. , Walsh, Naomi , Wheeler, William , Song, Lei , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Scélo, Ghislaine , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Fuchs, Charles S. , Gaziano, J. Michael , Hackert, Thilo , Hartge, Patricia, Hassan, Manal M. , Holly, Elizabeth A. , Hoover, Robert N. , Kirsten, Holger , Kurtz, Robert C. , Lee, I‐Min , Murphy, Neil , Ng, Kimmie , Oberg, Ann L. , Porta, Miquel , Rabe, Kari G. , Real, Francisco X. , Rothman, Nathaniel , Sesso, Howard D. , Thompson, Ian M. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Zeleniuch‐Jacquotte, Anne , Shi, Jianxin , Li, Donghui , Petersen, Gloria M. , Wolpin, Brian M. , Platz, Elizabeth A. , Arslan, Alan A , Canzian, Federico , Giles, Graham G , Bamlet, William R , Brennan, Paul , Hackert, Thilo , Katzke, Verena , Kirsten, Holger , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Wactawski-Wende, Jean , Yu, Herbert , Duell, Eric J , Amundadottir, Laufey , Li, Donghui , Klein, Alison P , Stolzenberg-Solomon, Rachael , Chaffee, Kari G. , Hung, Rayjean J , Visvanathan, Kala , Yuan, Fangcheng , Murphy, Neil , Porta, Miquel , Real, Francisco X , Thompson, Ian M , Zeleniuch-Jacquotte, Anne , Zhang, Han , Freeman, Laura E. Beane , Canzian, Federico , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Rosendahl, Jonas , Shu, Xiao‐Ou , White, Emily , Zheng, Wei , Albanes, Demetrius , Amiano, Pilar , Bamlet, William R. , Campbell, Peter T. , Chanock, Stephen Jacob , Goggins, Michael , Malats, Núria , Milne, Roger L. , Silverman, Debra T. , Wang, Xiaoliang , Wilkens, Lynne R. , Yu, Kai , Duell, Eric J. , Ámundadóttir, Laufey T. , Risch, Harvey A. , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

Cancer Research | July 8, 2020 | Volume: 80 | Issue: 18 | Pages: 4004-4013

10.1158/0008-5472.can-20-0447 | PMID 32641412 Get It

Abstract Registry-based epidemiologic studies suggest associations between chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma (PDAC). As genetic susceptibility contributes to a large proportion of chronic inflammatory intestinal diseases, we hypothesize that the genomic regions surrounding established genome-wide associated variants for these chronic inflammatory diseases are associated with PDAC. We examined the association between PDAC and genomic regions (±500 kb) surrounding established common susceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel disease, celiac disease, chronic pancreatitis, and primary sclerosing cholangitis. We analyzed summary statistics from genome-wide association studies data for 8,384 cases and 11,955 controls of European descent from two large consortium studies using the summary data-based adaptive rank truncated product method to examine the overall association of combined genomic regions for each inflammatory disease group. Combined genomic susceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis were associated with PDAC at P values &lt; 0.05 (0.0040, 0.0057, 0.011, and 3.4 × 10−6, respectively). After excluding the 20 PDAC susceptibility regions (±500 kb) previously identified by GWAS, the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowel disease remained associated with PDAC (P = 0.0029, 0.0057, and 0.0098, respectively). Genomic regions for celiac disease (P = 0.22) and primary sclerosing cholangitis (P = 0.078) were not associated with PDAC. Our results support the hypothesis that genomic regions surrounding variants associated with inflammatory intestinal diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis are associated with PDAC. Significance: The joint effects of common variants in genomic regions containing susceptibility loci for inflammatory bowel disease and chronic pancreatitis are associated with PDAC and may provide insights to understanding pancreatic cancer etiology.
Immune Checkpoint Inhibitor-Induced Bilateral Phrenic Neuropathy
Anderson, D., Olson, Eric J.

Mayo Clinic

B36. CASE REPORTS IN BIOLOGIC AND CHEMOTHERAPEUTIC AGENT INDUCED LUNG DISEASE | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A3143-A3143

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3143 Get It